Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects

British Journal of Clinical Pharmacology

Volumn 45, Issue 5, 1998, Pages 485-490

  Deneer, V H M ^a   Lie A Huen, L ^a   Kingma, J H ^a   Proost, J H ^b   Kelder, J C ^a   Brouwers, J R B J ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Atrial fibrillation; Atrial flutter; Cisapride; Episodic treatment; Healthy subjects; Interaction; Pharmacokinetics; Sotalol; Sublingual; Supraventricular tachycardia

Indexed keywords

CISAPRIDE; SOTALOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUTION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; TABLET;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ADULT; ANTI-ARRHYTHMIA AGENTS; BIOLOGICAL AVAILABILITY; CISAPRIDE; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; PIPERIDINES; SOTALOL; SYMPATHOMIMETICS;

EID: 0031971064     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00706.x     Document Type: Article

References (30)

1. Squire A, Goldman ME, Kupersmith J, Stern EH, Fuster V, Schweitzer P. Long-term antiarrhythmic therapy: problem of low drug levels and patients noncompliance. Am J Med 1984; 77: 1035-1038.
2. Margolis B, De Silva RA, Lown B. Episodic drug treatment in the management of paroxysmal arrhythmias. Am J Cardiol 1980; 45: 621-626.
3. Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrilation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J 1995; 129: 739-748.
4. Jordaens L, Gorgels A, Stroobandt R, Temmerman J. Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. Am J Cardiol 1991; 68: 35-40.
5. Rawles JM. What is meant by a 'controlled' ventricular rate in atrial fibrillation? Br Med J 1990; 63: 157-161.
6. Le Coz F, Funck-Brentano C, Poirier JM, Kibleur Y, Mazoit FX, Jaillon P. Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers. Clin Pharmacol Ther 1992; 52: 417-426.
7. Ishizaki T, Hirayama H, Tawara K, Nakaya H, Sato M, Sato K. Pharmacokinetics and pharmacodynamics in young, normal and elderly hypertensive subjects: a study using sotalol as a model drug. J Pharmacol Exp Ther 1979; 212: 173-181.
8. Anttila M, Arstila M, Pfeffer M, Tikkanen R, Vallinkoski V, Sundquist M. Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol 1976; 39: 118-128.
9. Gilberts RJ, Dodds WJ, Kahrilas PJ, Hogan WJ, Lipman S. Effect of cisapride, a new prokinetic agent, on oesophageal motor function. Dig Dis Sci 1987; 32: 1331-1336.
10. Baeyens R, Reyntjens A, Verlinden M. Cisapride accelerates gastric emptying and mouth-to-caecum transit of a barium meal. Eur J Clin Pharmacol 1984; 27: 315-318.
11. Kresvsky B, Malmud LS, Maurer AH, Somers MB, Siegel JA Fisher RS. The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1987; 1: 293-304.
12. Lie-A-Huen L. Pharmacokinetics and clinical pharmacology of flecainide in episodic treatment of paroxysmal atrial fibrillation. Thesis, University of Groningen, The Netherlands, 1991.
13. World Health Organisation. Drug interactions predisposing to ventricular arrhythmias. WHO Drug Information 1996; 10: 85-86.
14. De Boer A, De Leede LGJ, Breimer DD. Drug absorption by sublingual and rectal routes. Br J Anaesth 1984; 56: 69-82.
15. LeBrun PPH, Fox PLA, Vries de ME, Boddé HE. In vitro penetration of some ß-adrenoreceptor blocking drugs through porcine buccal mucosa. Int J pharm 1989; 49: 141-145.
16. Kimura M, Umemura K, Ikeda Y, et al. Pharmacokinetics and pharmacodynamics of (±)-sotalol in healthy male volunteers. Br J Clin Pharmacol 1996; 42: 583-588.
17. IJmker J, Bouma P, Uges DRA. Bepaling van sotalol. Ziekenhuisfarmacie 1991; 7: 32.
18. Kärkkäinen S. High-performance liquid chromatographic determination of sotalol in biological fluids. J Chromatogr 1984; 336: 313-319.
19. Proost JH. Wagner's exact Loo-Riegelman equation: the need for a criterion to choose between the linear and logarithmic trapezoidal rule. J Pharm Sci 1985; 74: 793-794.
20. Proost JH. Application of a numerical deconvolution technique in the assessment of bioavailability. J Pharm Sci 1985; 74: 1135-1136.
21. Proost JH. Critical evaluation of the determination of bioavailability by numerical deconvolution. Thesis, University of Groningen, The Netherlands 1987.
22. Rowbotham DJ, Milligan K, McHugh P. Effect of single doses of cisapride and ranitidine administered simultaneously on plasma concentrations of cisapride and ranitidine. Br J Anaesth 1991; 67: 302-305.
23. Bateman DN. The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur J Clin Pharmacol 1986; 30: 205-208.
24. Kirch W, Janisch HD, Ohnhaus EE, Peer van A. Cisapridecimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit 1989; 11: 411-414.
25. Rowbotban DJ, Parnacott S, Nimmo WS. No effect of cisapride on paracetamol absorption after oral simultaneous administration. Eur J Clin Pharmacol 1992; 42: 235-236.
26. Kirch W, Janisch HD, Santos SR, Duhrsen U, Dylewicz P, Ohnhaus EE. Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinet 1986; 11: 249-250.
27. McCallum RW, Prakash C, Campoli-Richards DM, Goa KL Cisapride: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988; 36: 652-681.
28. Brown HC, Carruthers SG, Kelly JG, McDevitt DG, Shanks RG. Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol 1976; 9: 367-372.
29. Henry JA, Ohashi K, Wadsworth J, Turner P. Drug recovery following buccal absorption of propranolol. Br J Clin Pharmacol 1980; 10: 61-65.
30. Fogelman F, Lightman SL, Sillet RW, McNicoll MW. The treatment of cardiac arrhythmias with sotalol. Eur J Clin Pharmacol 1972; 5: 72-76.